Help
Category:EMA approved in 2022
From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation
Jump to search
Pages in category "EMA approved in 2022"
The following 18 pages are in this category, out of 18 total.
A
Asciminib (Scemblix)
C
Capmatinib (Tabrecta)
Ciltacabtagene autoleucel (Carvykti)
E
Enfortumab vedotin (Padcev)
L
Lisocabtagene maraleucel (Breyanzi)
Loncastuximab tesirine (Zynlonta)
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
M
Melphalan flufenamide (Pepaxto)
Mosunetuzumab (Lunsumio)
N
Nivolumab and relatlimab (Opdualag)
R
Relugolix (Orgovyx)
S
Sotorasib (Lumakras)
Sutimlimab (Enjaymo)
T
Tabelecleucel (Ebvallo)
Tebentafusp (Kimmtrak)
Teclistamab (Tecvayli)
Tepotinib (Tepmetko)
V
Voxelotor (Oxbryta)
Category
:
EMA approved drugs
Navigation menu
Personal tools
Create account
Log in
Namespaces
Category
Discussion
Variants
Views
Read
View source
View history
More
Search
Index
Main page
Disclaimer
Editorial board
Content tutorial
Want to add info?
Top cancer pages
1. DLBCL
2. Breast cancer
3. NSCLC
4. Colorectal cancer
5. AML
6. Multiple myeloma
7. B-ALL
8. Pancreatic cancer
9. Bladder cancer
10. H & N cancer
References
Drug index
Vesicants & irritants
ICD billing codes
CPT E&M billing codes
Antiemetic support
Pathology
Performance status
Procedures
Steroid conversions
Consults
Fellowship programs
External links
Stay in touch
Like on Facebook
LinkedIn
Mailing list
Contributors
Contribution scores
Editing tutorial
Style guide
What's new
Tools
What links here
Related changes
Special pages
Printable version
Permanent link
Page information
Browse properties